Close Menu

NEW YORK (GenomeWeb) – Invivoscribe announced today that it has received approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA)for its LeukoStrat CDx FLT3 Mutation Assay companion diagnostic.

The firm expects to begin shipments of the FTL3 assay from LabPMM GK, the assay's marketing authorization holder in Japan, in late 2018.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.